Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

  • 25 January 2014 to 30 September 2015
  • Awards: Pump-priming Awards

This project confirmed acceptable performance of the new-generation intact FGF-23 assay (Immutopics, Inc) and the Fetuin A assay (Epitope Diagnostics, Inc; within- and between-batch precision CVs <20%, linearity r2>0.99).  We established that the discrepancy in results between our previous FGF-23 stability studies and published reports was due to differences in sample handling during the experiments.  Our approach of using separate vacutainers that were only opened at the particular time-point (as in samples collected for a randomised controlled trial) resulted in <5% change in plasma FGF-23 concentration following a delay in processing of up to 6 hours at room temperature or 24 hours chilled, compared with >17% change for repeat sampling from one vacutainer.  Plasma concentrations of Fetuin A changed by <3.5% in chilled samples up to 24 hours, but exhibited greater variability at room temperature.  We conclude that both analytes could be measured reliably in samples from HPS and SHARP.